RJFSA
LCTX icon

Raymond James Financial Services Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$9.51K Sell
10,507
-1,900
-15% -$1.76K ﹤0.01% 3422
2024
Q2 		$12.4K Buy
+12,407
New +$13.7K ﹤0.01% 3369
2022
Q1 		– Sell
-13,961
Closed -$34K – 3404
2021
Q4 		$34K Sell
13,961
-400
-3% -$936 ﹤0.01% 3217
2021
Q3 		$36K Sell
14,361
-2
-0% -$5 ﹤0.01% 3208
2021
Q2 		$41K Buy
14,363
+402
+3% +$1.04K ﹤0.01% 3225
2021
Q1 		$33K Buy
13,961
+1,886
+16% +$4.53K ﹤0.01% 3122
2020
Q4 		$21K Sell
12,075
-2,985
-20% -$4.17K ﹤0.01% 2948
2020
Q3 		$14K Sell
15,060
-1,144
-7% -$1.01K ﹤0.01% 2837
2020
Q2 		$14K Buy
+16,204
New +$14.3K ﹤0.01% 2778
2020
Q1 		– Sell
-19,860
Closed -$18K – 2669
2019
Q4 		$18K Sell
19,860
-22,781
-53% -$19K ﹤0.01% 2806
2019
Q3 		$42K Sell
42,641
-130
-0.3% -$135 ﹤0.01% 2713
2019
Q2 		$47K Sell
42,771
-4,297
-9% -$4.95K ﹤0.01% 2750
2019
Q1 		$62K Buy
47,068
+13,383
+40% +$16.6K ﹤0.01% 2689
2018
Q4 		$31K Sell
33,685
-39,833
-54% -$61K ﹤0.01% 2494
2018
Q3 		$151K Buy
73,518
+115
+0.2% +$242 ﹤0.01% 2600
2018
Q2 		$132K Sell
73,403
-5,715
-7% -$11.5K ﹤0.01% 2571
2018
Q1 		$186K Buy
79,118
+6,286
+9% +$14.7K ﹤0.01% 2282
2017
Q4 		$137K Buy
72,832
+38,131
+110% +$83.3K ﹤0.01% 2342
2017
Q3 		$86K Buy
34,701
+5,600
+19% +$13.9K ﹤0.01% 2406
2017
Q2 		$80K Buy
29,101
+1,258
+5% +$3.52K ﹤0.01% 2370
2017
Q1 		$84K Buy
27,843
+114
+0.4% +$324 ﹤0.01% 2280
2016
Q4 		$88K Buy
27,729
+11,727
+73% +$36K ﹤0.01% 2204
2016
Q3 		$55K Hold
16,002
– – ﹤0.01% 2200
2016
Q2 		$37K Buy
16,002
+1,143
+8% +$2.8K ﹤0.01% 2193
2016
Q1 		$37K Buy
+14,859
New +$33.2K ﹤0.01% 1985

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Raymond James Financial Services Advisors's LCTX Position: Q3 2024 in Review

Raymond James Financial Services Advisors reduced its Lineage Cell Therapeutics (LCTX) stake by 15% in Q3 2024, selling an estimated $1.76K and leaving 10,507 shares worth $9.51K. The position accounts for ﹤0.01% of the portfolio, ranked #3422.

Raymond James Financial Services Advisors first reported a position in LCTX in Q1 2016 and has held it in 25 quarters since. The position peaked at $186K in Q1 2018. 114 funds tracked by Wall St. Rank hold LCTX as of Q3 2024.

  • Raymond James Financial Services Advisors held 10,507 shares of Lineage Cell Therapeutics worth $9.51K as of Q3 2024.
  • Raymond James Financial Services Advisors sold 1,900 Lineage Cell Therapeutics shares in Q3 2024, an estimated $1.76K.
  • Lineage Cell Therapeutics made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #3422 holding.
  • Raymond James Financial Services Advisors first reported a position in Lineage Cell Therapeutics in Q1 2016 and has held it in 25 quarters since.
  • Raymond James Financial Services Advisors's Lineage Cell Therapeutics position peaked at $186K in Q1 2018.
  • 114 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.